Oncology Precision Medicine Market SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)
Oncology Precision Medicine Market is segmented By Type of Cancer (Bladder Cancer, Blood / Hematologic Cancer, Breast Cancer, Cervical Cancer, Gastrointestinal Cancer, Head and Neck Squamous Cell Cancer, Lung Cancer, Skin Cancer, Others), By Route of Administration (Oral, Intravenous, Others), By Type of Molecule (Small Molecules, Biologics), By Drug Class (Kinase Inhibitors, Enzyme Inhibitors, Immune Checkpoint Inhibitors, Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa). The report offers the value (in USD Billion) for the above-mentioned segments.
Oncology Precision Medicine Market Size
Market Size in USD
CAGR8.8%
| Study Period | 2024 - 2031 |
| Base Year of Estimation | 2023 |
| CAGR | 8.8% |
| Market Concentration | High |
| Major Players | AstraZeneca, Novartis, Pfizer, Bristol-Myers Squibb, Roche |
please let us know !
Oncology Precision Medicine Market Analysis
The Global Oncology Precision Medicine Market is estimated to be valued at USD 141.11 billion in 2024 and is expected to reach USD 257.21 billion by 2031, growing at a compound annual growth rate (CAGR) of 8.8% from 2024 to 2031. Precision oncology focuses on therapies and diagnostics tailored for each patient's specific genes, environment, and lifestyle. The approach analyzes a patient's genetic makeup and matches them with available targeted therapies.
The market is expected to witness significant growth due to rising prevalence of cancer worldwide and increasing application of personalized medicine in oncology. Furthermore, advancements in genomics and availability of companion diagnostic tests are helping doctors provide customized treatment plans based on a deep understanding of an individual patient's tumor biology. Continuous research into understanding cancer at molecular level will further drive adoption of precision oncology practices.